Loading clinical trials...

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

Implementation of Onsite, Rapid Antiretroviral Therapy (ART) Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

NCT04650269•University of Miami

View on ClinicalTrials.gov

Summary

The purpose of this study is to see if providing HIV medicine right away at the IDEA Syringe Services Program will help the participant start and remain in HIV care, including having no detectable HIV in the participant's blood.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Adult (age\>18 years);
•2. positive rapid HIV test;
•3. ability to provide informed consent;
•4. HIV RNA \> 200 copies/ml;
•5. creatinine clearance \> 30 mg/dl as measured by serum creatinine;
•6. no allergy to bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) as indicated by patient history and self-reported allergies.

Exclusion Criteria

•1\) Any other comorbidities at the discretion of the investigator

Locations (1)

University of Miami

Miami, Florida, United States

Key Dates

Start Date

March 4, 2021

Primary Completion Date

December 31, 2023

Completion Date

December 31, 2023

Last Updated

January 8, 2025

Enrollment

ACTUAL participants

Conditions

Harm ReductionHIV InfectionsDrug Use

Interventions

Biktarvy 50Mg-200Mg-25Mg Tablet

DRUG

HIV care

OTHER

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

NCT07199335

HIVSubstance Use Disorder (SUD)+1 more

View study

RECRUITINGNA

Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers

NCT06372899

E-cigarette UseCigarette Smoking+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

Inclusion Criteria

Exclusion Criteria

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers

Skeletal Muscle Energetics and Fatiguability in Older Individuals

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention